A new chapter for the MA Switzerland group

In recent years, Switzerland has witnessed a growing interest in medical cannabis and its therapeutic applications. At the same time, the regulatory framework has evolved to allow solid and reliable companies to contribute to the development of a highly controlled sector.
Within this context, MA Switzerland Production Sagl has reached a significant milestone: obtaining official authorization from Swissmedic to cultivate cannabis for medical purposes.

This marks an important moment in the company’s history. The authorization does not replace its CBD cannabis production — active since 2018 — but complements it, enriching the group’s expertise and opening the door to new opportunities for collaboration within the therapeutic field.

A recognition that reflects seven years of experience

Since 2018, MA Switzerland Production Sagl has been dedicated to producing high-quality CBD cannabis, gradually building a model founded on precision, reliability, and transparency.

The Swissmedic authorization therefore stands as a natural evolution: the result of ongoing investment, accumulated know-how, and a clear vision of what the plant can offer within a modern medical landscape.

Although medical cannabis differs from CBD, its cultivation is rooted in the strong foundations the company has developed: agronomic expertise, rigorous protocols, secured infrastructures, and a corporate culture deeply committed to quality.

What does obtaining Swissmedic authorization mean?

The authorization enables MA Switzerland Production Sagl to cultivate high-THC cannabis exclusively for the medical sector.
This means that the cultivated flowers will be supplied solely to authorized partners — pharmaceutical companies, compounding pharmacies, or other entities permitted by Swiss law.

This production is not intended for the public or the recreational market.
Cultivation takes place within a strictly regulated environment, where every stage must meet high standards: security, traceability, documentation, and full compliance with Swissmedic requirements.

Medical cannabis: a growing sector in Switzerland

Switzerland has strengthened and clarified the regulations surrounding medical cannabis, providing a reliable framework for companies capable of meeting the required standards.

Interest in therapeutic cannabis continues to rise, supported by healthcare professionals and scientific progress, creating an increasing demand for high-quality raw materials.

MA Switzerland Production Sagl’s entry into this field responds directly to this need: contributing with professionalism, seriousness, and transparency to a sector undergoing structured development.

An expansion of activity, not a change of direction

It is important to state clearly:

MA Switzerland Production Sagl is not leaving the CBD sector.

CBD cannabis production remains a central pillar of the company’s daily work.

Medical cannabis cultivation represents a second, complementary pillar, allowing the group to leverage its existing expertise and expand its scope.

The two activities do not compete with one another — they strengthen each other.

CBD continues on its own path with its unique identity, while medical cannabis opens the door to new partnerships, research opportunities, and long-term development.

Looking ahead: quality, collaboration, and innovation

For MA Switzerland Production Sagl, this Swissmedic authorization is not the final goal, but a starting point.
The coming years will be dedicated to strengthening the company’s position within the Swiss sector, building partnerships with medical actors, and continuously refining cultivation and quality-control processes.

The company will remain committed to:

• innovation and infrastructure improvement,
• sustainability and process precision,
• complete transparency across the production chain,
• ongoing training and skill development,
• strong partnerships with pharmaceutical operators in Switzerland and abroad.

The mission remains unchanged: delivering impeccable products and contributing positively to a sector undergoing rapid transformation.

A chapter that begins, not one that ends

Obtaining Swissmedic authorization represents one of the most significant stages in the evolution of the MA Switzerland group.
It validates years of dedicated work while opening the way to new professional and human opportunities.

MA Switzerland Production Sagl will continue producing CBD cannabis with the same dedication as always, while now developing a complementary activity focused on medical cannabis — a strategic choice that further reinforces the company’s mission: promoting quality, professionalism, and innovation within a rapidly evolving sector.